1. Norway Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Lytix Biopharma AS

Lytix Biopharma AS

LYTIX.OL
Lytix Biopharma ASNO flagOslo Stock Exchange
9.68
NOK
+0.18
- -
608.23MMarket Cap
Lytix Biopharma AS
LYTIX.OL
(Oslo Stock Exchange)

Recent

price

9.68

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.01
0.01
- -
0.58
0.28
0.1
0.2
- -
- -
Revenue per Share
-1.58
-0.83
-1.08
-1.44
-1.41
-2.18
-1.73
-0.88
-1.03
Basic EPS, GAAP
-1.87
-0.95
-0.63
-1.34
-1.33
-2.39
-1.29
-0.87
-1.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.06
0.06
0.07
0.12
0.1
0.1
0.13
0.1
0.11
Book Value per Share
1.05
0.35
0.51
5.69
3.39
1.27
1.98
0.9
1.62
Tangible Book Value per Share
39
39
39
33
40
40
54
69
71
Basic Weighted Avg Shares
- -
- -
- -
19
11
4
11
- -
- -
Sales/Revenue/Turnover
-18,506.82
-10,632.58
-1,412,400
-248.54
-595.28
-2,425.08
-861.38
- -
- -
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
1
Depreciation Expense
-62
-32
-42
-48
-56
-88
-94
-60
-73
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-18,253.71
-10,456.45
-1,402,933.33
-249.02
-508.29
-2,202.38
-846.72
- -
- -
Profit Margin (%)
41
14
20
190
134
51
107
61
114
Working Capital
- -
- -
- -
- -
- -
- -
2
1
1
LT Debt
41
14
20
190
135
51
108
62
114
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-1,428.6
-1,713.68
-1,480.04
-1,422.89
-2,193.59
-1,741.94
-879.37
-1,005.69
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
77
Market Capitalization
470
678
728

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
93
79
127
Cash, Cash Equivalents & STI
90
72
120
Accounts Receivable, Net
3
- -
7
Inventories
- -
- -
- -
Total Current Liabilities
16
19
13
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
166.02%
-42.77%
Free Cash Flow
- -
28.32%
-14.95%
Net Income, GAAP
- -
11.7%
-36.37%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11
- -
- -
- -
11
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.36
-0.48
-0.33
-0.54
-1.73
2025
-0.19
-0.07
-0.34
-0.27
-0.88
2026
-0.34
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Ovoca Bio plc (OVB.L)
Purple Biotech Ltd. (PPBT.TA)
MEI Pharma, Inc. (MEIP)
Synaptogenix, Inc. (SNPX)
Talaris Therapeutics, Inc. (TALS)
Adial Pharmaceuticals, Inc. (ADIL)
Business
Lytix Biopharma AS, a clinical-stage biotechnology company founded in 2003 and headquartered in Oslo, Norway, develops novel cancer immunotherapies based on host-defense peptide-derived molecules that selectively kill cancer cells and activate the patient's immune system. The company's lead product candidate, ruxotemitide (formerly LTX-315), is an oncolytic peptide in Phase II clinical trials for indications including neoadjuvant melanoma, basal cell carcinoma, and other solid tumors; it functions by inducing immunogenic cell death, promoting tumor infiltration by lymphocytes, and serving as a source of patient-specific antigens for sustained immune responses. Additional pipeline assets include LTX-401, a proprietary molecule in late preclinical development targeting deep-seated tumors, with strategic plans for clinical advancement informed by positive regulatory feedback. Lytix grants exclusive licenses for its technologies, such as the 2020 royalty-bearing agreement with Verrica Pharmaceuticals Inc. for ruxotemitide development, manufacturing, and commercialization in non-melanoma skin cancers. Operations focus on the biopharmaceutical sector, primarily serving patients with advanced solid tumors through collaborations with international research institutions, hospitals, and partners in the United States and Europe. Recent developments include positive Phase II data for ruxotemitide announced post-Q3 2025, featuring a 97% objective response rate and 51% complete histologic clearance in basal cell carcinoma from Verrica's study, alongside 88% overall pathological response in neoadjuvant melanoma with no relapses reported; these results prompted acceleration of the development strategy toward Phase III trials. In December 2024, Lytix raised NOK 100 million and EUR 1 million through a directed share issue and primary bid offering to fund milestones, extending runway into 2026, while Verrica secured USD 40 million for its programs including potential basal cell carcinoma Phase III. Q3 2025 financials reflected a net loss of NOK 11.5 million amid pipeline progress, with ongoing investigator-sponsored NeoLIPA trial recruitment in neoadjuvant melanoma combined with PD-1 inhibitors and openness to new partnerships for global expansion.